Patents by Inventor Robin Barbour

Robin Barbour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210130449
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Patent number: 10961302
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: March 30, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Publication number: 20210032319
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: July 20, 2020
    Publication date: February 4, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter SEUBERT, Philip James DOLAN, III, Yue LIU, Robin BARBOUR
  • Patent number: 10906964
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 2, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu
  • Publication number: 20210017278
    Abstract: Methods for the treatment of AL amyloidosis associated with the deposition of misfolded immunoglobulin light chain proteins and corresponding uses related to an antibody, such as a 2A4 antibody, or a pharmaceutical formulation comprising the antibody.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 21, 2021
    Applicant: Prothena Biosciences Limited
    Inventors: Tarlochan S. NIJJAR, Philip J. DOLAN, Robin BARBOUR
  • Patent number: 10889638
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 12, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Patent number: 10889636
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 12, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Patent number: 10875910
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: December 29, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
  • Patent number: 10852309
    Abstract: The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: December 1, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Lynn R. Zieske, Sarah Hamren
  • Publication number: 20200369755
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: March 3, 2020
    Publication date: November 26, 2020
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Tarlochan S. Nijjar, Robin BARBOUR, Philip James DOLAN, III, Yue LIU, Svetlana ALEXANDER, Mark RENZ
  • Publication number: 20200331992
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, and for monitoring the efficacy of TTR therapies, among other applications.
    Type: Application
    Filed: October 5, 2018
    Publication date: October 22, 2020
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Joshua Reginald SALMANS, Svetlana ALEXANDER, Robin BARBOUR, Jeffrey N. HIGAKI, Tarlochan S. NIJJAR
  • Publication number: 20200317763
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer' s disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Application
    Filed: April 23, 2020
    Publication date: October 8, 2020
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
  • Publication number: 20200299397
    Abstract: The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).
    Type: Application
    Filed: February 6, 2020
    Publication date: September 24, 2020
    Inventors: Robin Barbour, Kate Dora Games-Thiel, Tarlochan S. Nijjar, Wagner Zago, Olaf Mundigl, Jens Niewoehner, Georg Tiefenthaler
  • Patent number: 10752679
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: August 25, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Publication number: 20200249244
    Abstract: The invention provides methods of detecting transthyretin (TTR) using a capture antibody and a reporter antibody. The capture antibody binds preferentially to misfolded TTR over native tetrameric form of TTR. The capture antibody binds to an epitope within amino acid residues 89-97 or TTR or to an epitope within amino acid residues 101-109 of TTR. 9D5 and 18C5 are examples of suitable capture antibodies. The methods can be used for diagnosing diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis) and for monitoring the efficacy of TTR therapies, among other applications.
    Type: Application
    Filed: October 5, 2018
    Publication date: August 6, 2020
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Joshua Reginald SALMANS, Svetlana ALEXANDER, Robin BARBOUR, Jianmin LI, Jeffrey N. HIGAKI, Tarlochan S. NIJJAR
  • Patent number: 10669331
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: June 2, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
  • Patent number: 10654920
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: May 19, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Publication number: 20200123239
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 23, 2020
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Patent number: 10562973
    Abstract: The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: February 18, 2020
    Assignees: Prothena Bioscience Limited, Hoffmann-LaRoche Inc.
    Inventors: Robin Barbour, Kate Dora Games-Thiel, Tarlochan S. Niijar, Wagner Zago, Olaf Mundigl, Jens Niewoehner, Georg Tiefenthaler
  • Patent number: 10501531
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: December 10, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour